Skip to main content

MoneyWorks4Me

Oxygenta Pharma - Quaterly Results

11 Nov 2026 Evaluate
The total revenue hovered 134.19% to Rs. 334.94 millions for the September 2026 quarter as against Rs. 143.02 millions during the corresponding quarter last year.The Net Loss for the quarter ended September 2026 is Rs. -27.35 millions as compared to Net Loss of Rs. -49.31 millions of corresponding quarter ended September 2025 Operating profit Margin for the quarter ended September 2026 improved to 0.49% as compared to -46.31% of corresponding quarter ended September 2025


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202609 202509 % Var 202609 202509 % Var 202603 202503 % Var
Sales 334.94 143.02 134.19 704.91 294.37 139.46 1129.82 1092.99 3.37
Other Income 0.20 -0.56 -135.71 0.43 1.13 -61.95 2.86 13.09 -78.15
PBIDT 0.49 -46.31 -101.06 6.19 -112.92 -105.48 -150.80 -87.76 71.83
Interest 27.30 9.50 187.37 51.89 15.78 228.83 47.77 19.61 143.60
PBDT -26.81 -55.81 -51.96 -45.70 -128.82 -64.52 -198.57 -107.37 84.94
Depreciation 7.14 8.57 -16.69 13.32 17.04 -21.83 23.23 36.14 -35.72
PBT -33.95 -64.38 -47.27 -59.02 -145.86 -59.54 -221.80 -143.51 54.55
TAX -6.60 -15.07 -56.20 -10.64 -35.49 -70.02 -46.09 -40.53 13.72
Deferred Tax -6.60 -15.07 -56.20 -10.64 -35.49 -70.02 -46.09 -42.13 9.40
PAT -27.35 -49.31 -44.53 -48.38 -110.37 -56.17 -175.71 -102.98 70.63
Equity 369.84 369.84 0.00 369.84 369.84 0.00 369.84 369.84 0.00
PBIDTM(%) 0.15 -32.38 -100.45 0.88 -38.36 -102.29 -13.35 -8.03 66.23
Peers
Company Name CMP
Sun Pharma. Inds. 1912.65
Dr. Reddys Labs. 1390.60
Cipla 1423.40
Lupin 1991.70
Zydus Lifesciences 1200.00
View more..